Related Experiment Video

Updated: Jul 17, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.1K

Treatment discontinuation patterns of anti-VEGF in retinal vein occlusion

Amy Basilious1, Julie Duncan2, Bobbi Smuck2

  • 1Department of Ophthalmology, Ivey Eye Institute, St. Joseph's Health Care, London, ON..

Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|September 5, 2023
PubMed
Abstract

Insights

Anti-vascular endothelial growth factor (anti-VEGF) treatment for retinal vein occlusions (RVO) was discontinued in most patients, often due to stable disease. Branch retinal vein occlusion (BRVO) patients generally had better outcomes than central retinal vein occlusion (CRVO) patients.

Area of Science:

  • Ophthalmology
  • Retinal diseases
  • Medical treatments

Background:

  • Retinal vein occlusions (RVO) are a significant cause of vision loss.
  • Anti-vascular endothelial growth factor (anti-VEGF) therapy is a common treatment for RVO.
  • Understanding real-world treatment patterns is crucial for optimizing patient care.

Purpose of the Study:

  • To analyze real-world anti-VEGF treatment patterns in patients with retinal vein occlusions (RVO).
  • To identify reasons for treatment discontinuation and factors influencing outcomes.

Main Methods:

  • Retrospective cohort study of treatment-naive RVO patients from 2015-2021.
  • Data collected included demographics, diagnosis, injection frequency, treatment duration, and visual acuity.
  • Statistical analyses compared outcomes between branch RVO (BRVO) and central RVO (CRVO) and discontinuation subgroups.

Main Results:

  • A total of 219 eyes were analyzed, with 2482 anti-VEGF injections administered.
  • The discontinuation rate was 76.7%, with stable disease being the most common reason (45% of all RVOs).
  • Central RVO (CRVO) eyes had worse baseline and final visual acuity compared to branch RVO (BRVO) eyes, though both groups improved.

Conclusions:

  • Anti-VEGF treatment for RVO is frequently discontinued, primarily due to disease stability.
  • Branch RVO (BRVO) patients achieved better visual outcomes than central RVO (CRVO) patients.
  • Despite discontinuation, anti-VEGF therapy demonstrated benefit for both RVO subtypes.

More Related Videos

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

2.7K
Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

8.5K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
477
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
560
Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
15
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
200